DeepMed Research

University Hospital Tuebingen

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1388-01-01

Employees: -

Market Cap: -

Website: https://www.klinikum.uni-heidelberg.de/Startseite.2.0.html?&no_cache=1

Clinical Trials

Lesser Toe PIP Joint Arthrodesis Versus Resection Arthroplasty

Not Applicable

Completed

Conditions: Lesser Toe Deformity
Claw Toe

Interventions: Procedure: Arthrodesis
Procedure: Resection arthroplasty

First Posted Date: 2018-05-21

Last Posted Date: 2018-05-21

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 37

Registration Number: NCT03530839

Dopamine Action on Metabolism in Relation to Genotype

Phase 2

Recruiting

Conditions: Obesity

Interventions: Other: Placebo
Drug: Bromocriptine

First Posted Date: 2018-05-15

Last Posted Date: 2024-02-02

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 150

Registration Number: NCT03525002

Locations: 🇩🇪
University of Tuebingen, Department of Internal Medicine IV, Tübingen, Germany
🇩🇪
University Hospital Cologne, Cologne, Germany
🇩🇪
University Hospital Luebeck, Luebeck, Germany

Effects of tDCS-enhanced Cognitive Control Training on Depression

Not Applicable

Conditions: Depression Unipolar

Interventions: Other: 2mA tDCS
Other: 1mA tDCS
Behavioral: Cognitive control training

First Posted Date: 2018-05-08

Last Posted Date: 2019-02-19

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 57

Registration Number: NCT03518749

Locations: 🇩🇪
University Hospital Tuebingen, Tubingen, Baden-Württemberg, Germany

Molecular Tumor Board at the Center for Personalized Medicine Tübingen

Recruiting

Conditions: Advanced Cancer

First Posted Date: 2018-04-19

Last Posted Date: 2018-04-19

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 1000

Registration Number: NCT03503149

Locations: 🇩🇪
University Hospital Tübingen, Tübingen, BW, Germany

Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile

Phase 2

Terminated

Conditions: Acute Ischemic Stroke

Interventions: Drug: Medical oxygen
Other: Standard of care

First Posted Date: 2018-04-18

Last Posted Date: 2022-09-23

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 223

Registration Number: NCT03500939

Locations: 🇧🇪
KU Leuven, Leuven, Belgium
🇧🇪
UZ Gent, Gent, Belgium
🇫🇷
CHU de Grenoble, Grendelbruch, France

and more 19 locations

Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases

Recruiting

Conditions: Rare Diseases
Genetic Predisposition

Interventions: Genetic: NGS Diagnostic

First Posted Date: 2018-04-09

Last Posted Date: 2022-05-23

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 5500

Registration Number: NCT03491280

Locations: 🇩🇪
University Hospital, Tübingen, Germany

Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement

Phase 2

Withdrawn

Conditions: Visual Impairment
Bardet-Biedl Syndrome

Interventions: Drug: Metformin

First Posted Date: 2018-04-06

Last Posted Date: 2019-04-18

Lead Sponsor: University Hospital Tuebingen

Registration Number: NCT03490019

Combined Stimulation of STN and SNr for Dysphagia in Parkinson's Disease

Not Applicable

Conditions: Parkinson's Disease
Dysphagia

Interventions: Device: [STN+SNr]
Device: [standard STN]
Behavioral: Swallowing therapy

First Posted Date: 2018-03-19

Last Posted Date: 2018-05-30

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 20

Registration Number: NCT03470324

Locations: 🇩🇪
University of Tübingen, Tübingen, Germany

Tocilizumab for the Treatment of Familial Mediterranean Fever

Phase 2

Completed

Conditions: Familial Mediterranean Fever

Interventions: Drug: Tocilizumab Infusion RoAcemtra (EU)
Drug: 0.9% physiological saline

First Posted Date: 2018-02-26

Last Posted Date: 2020-11-18

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 30

Registration Number: NCT03446209

Locations: 🇩🇪
Universitätsklinikum Köln, Klinik I für Innere Medizin, Cologne, NRW, Germany
🇩🇪
Charité Universitätsmedizin Berlin, Klinik für Rheumatologie und Klinische Immunologie, Abteilung -Neue Therapien & Studien, Berlin, Germany
🇩🇪
University Hospital Tuebingen; Department of oncology, hematology, rheumatology, immunology and pulmology, Tuebingen, Germany

Empagliflozin Effect on Glucose Toxicity

Phase 4

Withdrawn

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: Empagliflozin (Jardiance®)
Drug: Insulin Glargine (Lantus®)

First Posted Date: 2018-02-19

Last Posted Date: 2024-05-16

Lead Sponsor: University Hospital Tuebingen

Registration Number: NCT03437330

Locations: 🇩🇪
German Diabetes Center, Leibniz-Center for Diabetes Research at the Heinrich-Heine-University Duesseldorf, Duesseldorf, North Rhine Westphalia, Germany
🇩🇪
University Hospital, Tuebingen, Baden-Württemberg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy